

RESEARCH Open Access

Prevalence of low central venous oxygen saturation in the first hours of intensive care unit admission and associated mortality in septic shock patients: a prospective multicentre study

Thierry Boulain^{1*}, Denis Garot², Philippe Vignon^{3,4}, Jean-Baptiste Lascarrou⁵, Arnaud Desachy⁶, Vlad Botoc⁷, Arnaud Follin⁸, Jean-Pierre Frat⁹, Frédéric Bellec¹⁰, Jean-Pierre Quenot^{11,12}, Armelle Mathonnet¹, Pierre-François Deguin² and for the Clinical Research in Intensive Care and Sepsis (CRICS) Group¹³

Abstract


Introduction: In septic shock patients, the prevalence of low (<70%) central venous oxygen saturation (ScvO2) on admission to the intensive care unit (ICU) and its relationship to outcome are unknown. The objectives of the present study were to estimate the prevalence of low ScvO2 in the first hours of ICU admission and to assess its potential association with mortality in patients with severe sepsis or septic shock.

Methods: This was a prospective, multicentre, observational study conducted over a one-year period in ten French ICUs. Clinicians were asked to include patients with severe sepsis or septic shock preferably within 6 hours of ICU admission and as soon as possible without changing routine practice. ScvO2 was measured at inclusion and 6 hours later (H6), by blood sampling.

Results: We included 363 patients. Initial ScvO2 below 70% was present in 111 patients and the pooled estimate for its prevalence was 27% (95% Confidence interval (95%Cl): 18% to 37%). At time of inclusion, among 166 patients with normal lactate concentration (≤ 2 mmol/L), 55 (33%) had a low initial ScvO2 (< 70%), and among 136 patients who had already reached the classic clinical endpoints for mean arterial pressure (≥ 65 mmHg), central venous pressure (≥ 8 mmHg), and urine output (≥ 0.5 mL/Kg of body weight), 43 (32%) had a low initial ScvO2 (< 70%). Among them, 49% had lactate below 2 mmol/L. The day-28 mortality was higher in case of low initial ScvO2 (37.8% versus 27.4%; P = 0.049). When adjusted for confounders including the Simplified Acute Physiology Score and initial lactate concentration, a low initial ScvO2 (Odds ratio (OR) = 3.60, 95%Cl: 1.76 to 7.36; P = 0.0004) and a low ScvO2 at H6 (OR = 2.18, 95%Cl: 1.12 to 4.26; P = 0.022) were associated with day-28 mortality by logistic regression.

Conclusions: Low ScvO2 was common in the first hours of admission to the ICU for severe sepsis or septic shock even when clinical resuscitation endpoints were achieved and even when arterial lactate was normal. A ScvO2 below 70% in the first hours of ICU admission and six hours later was associated with day-28 mortality.

¹Medical-Surgical Intensive Care Unit, Regional Hospital Center, Orléans, France





^{*} Correspondence: thierry.boulain@chr-orleans.fr

Introduction

Central venous oxygen saturation ($S_{cv}O_2$) has long been studied as a prognostic marker and resuscitation end-point in patients with shock [1]. It is an imperfect surrogate of mixed venous oxygen saturation (S_vO_2) because it reflects the oxygen supply-to-consumption ratio of the upper part of the body only. However, $S_{cv}O_2$ is simple to measure either continuously or intermittently, and spontaneous or therapy-induced changes in $S_{cv}O_2$ and S_vO_2 are closely correlated [2].

Based on these principles, Rivers et al. [3] showed that an early therapeutic strategy that includes aiming for the rapid normalization of $S_{cv}O_2$ ($\geq 70\%$) in patients suffering from severe sepsis or septic shock at presentation to the emergency department could improve survival. Since then, international guidelines have recommended targeting $S_{cv}O_2$ at $\geq 70\%$ during the first 6 hours of care in patients presenting with severe sepsis or septic shock [4]. However, this recommendation remains controversial. Indeed, resuscitation protocols including an S_{cv}O₂ target have been mostly tested in the emergency department [5-7], not after ICU admission. Importantly, after ICU admission, targeting normal S_{cv}O₂ is deemed to have little place, as S_{cv}O₂ is frequently considered to be already normalized on ICU admission [8]. However, the prevalence of low S_{cv}O₂ (<70%) in ICU septic patients is poorly known. It has been assessed only in two prospective studies of limited size [9,10], while other studies have only reported the mean initial value of S_{cv}O₂ [8,11]. In addition, the relationship between low $S_{cv}O_2$ and outcome is still unknown.

Since the Rivers study [3], the idea that the relationship between low $S_{cv}O_2$ and fatal outcome in septic patients has been widely demonstrated has remained. Up to now, however, such a relationship has not been demonstrated in multicentre prospective studies performed either in the emergency department [12] or in the ICU [10]. Accordingly, the aim of the present multicentre observational prospective study was to estimate the prevalence of low $S_{cv}O_2$ in patients presenting with severe sepsis or septic shock after ICU admission, and to assess its potential association with outcome.

Materials and methods

The study took place in 10 French medical-surgical adult ICUs (4 university hospitals, 1 regional and teaching hospital, and 5 general hospitals) with a combined total of 154 ICU beds. Participating ICUs were asked to screen consecutive patients presenting with sepsis and circulatory failure for potential inclusion in the study, over a period left at their discretion, from July 2011 to June 2012.

Clinicians were asked to include patients with severe sepsis or septic shock, preferably within 6 hours of ICU admission, and as soon as possible without changing

routine practice. Patients were included if they had circulatory failure of septic origin (that is, severe sepsis or septic shock [13]) within 12 hours after ICU admission, and had an intra-arterial and superior vena cava (internal jugular or subclavian) catheter in situ. Circulatory failure was defined by either the use of vasopressor (septic shock) or, in case of severe sepsis, by a mean arterial pressure <65 mmHg or a systolic arterial pressure <90 mmHg at least twice over a 15-minute period, associated with at least one condition reflecting tissue hypoperfusion or low flow state (see Table 1, Criteria for circulatory failure at inclusion). Patients were not included in the case of brain death, admission following cardiac arrest, or if imminent death was expected.

Measurements and data collection

The measurement of $S_{cv}O_2$ was performed as soon as possible (at the time defined as zero hours (H0)) by sampling blood from the superior vena cava through the central venous catheter, and at 6 hours after inclusion (H6). $S_{cv}O_2$ was either calculated from blood gas analysis by a standard blood gas analyser in four centres, or measured by a co-oximeter in six centres. Concomitantly, arterial blood was drawn at each time point for blood gas analysis and lactate measurement. Other demographic, clinical and laboratory data prospectively recorded are provided in Additional file 1. Independent data monitoring was conducted in each site to ascertain the accuracy of recorded information.

The Ethics Committee of the teaching hospital of Limoges, France, approved the protocol for all hospitals involved (agreement number 65-2011-11) and waived the need for prior informed consent because the study procedures fulfilled the criteria of a non-interventional study as defined by the French Law [17]. Patients' next-of-kin and then patients themselves if they regained capacity were informed of their participation and their right to refuse the use of the obtained data was clearly established.

Haemodynamic monitoring and treatment of shock followed international [18] and national guidelines [19] that corresponded to standard of care of the participating centres. However, none of the participating ICUs had implemented systematic treatment algorithms based on $S_{\rm cv}O_2$ monitoring.

Study objective

The study primary objective was to estimate the prevalence of low $S_{cv}O_2$ (<70%, but other thresholds were also tested) and to assess the possible association between low $S_{cv}O_2$ and day-28 mortality.

Data reporting and statistical analysis

Categorical data are expressed as percentages, and continuous variables are expressed as means \pm SD or

Table 1 Demographics, clinical characteristics, treatment and outcome in 363 patients

Male sex Age, years Severe sepsis at inclusion Nosocomial infection Source of infection Lung-pleura Abdomen Urine Skin, bones, joints Catheter Central nervous system Endocarditis Other Source not identified Underlying disease Chronic obstructive pulmonary disease Arterial hypertension Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion (in addition to recent or ongoing hypotension)	231 (63.6) 55.8 ± 14.1 25 (6.9) 338 (93.1) 98 (27.0) 165 (45.7) 83 (23.0) 45 (12.5) 30 (8.3)
Severe sepsis at inclusion Septic shock at inclusion Nosocomial infection Source of infection Lung-pleura Abdomen Urine Skin, bones, joints Catheter Central nervous system Endocarditis Other Source not identified Underlying disease Chronic obstructive pulmonary disease Arterial hypertension Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	25 (6.9) 338 (93.1) 98 (27.0) 165 (45.7) 83 (23.0) 45 (12.5) 30 (8.3)
Septic shock at inclusion Nosocomial infection Source of infection Lung-pleura Abdomen Urine Skin, bones, joints Catheter Central nervous system Endocarditis Other Source not identified Underlying disease Chronic obstructive pulmonary disease Arterial hypertension Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	338 (93.1) 98 (27.0) 165 (45.7) 83 (23.0) 45 (12.5) 30 (8.3)
Nosocomial infection Source of infection Lung-pleura Abdomen Urine Skin, bones, joints Catheter Central nervous system Endocarditis Other Source not identified Underlying disease Chronic obstructive pulmonary disease Arterial hypertension Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	98 (27.0) 165 (45.7) 83 (23.0) 45 (12.5) 30 (8.3)
Source of infection Lung-pleura Abdomen Urine Skin, bones, joints Catheter Central nervous system Endocarditis Other Source not identified Underlying disease Chronic obstructive pulmonary disease Arterial hypertension Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	165 (45.7) 83 (23.0) 45 (12.5) 30 (8.3)
Abdomen Urine Skin, bones, joints Catheter Central nervous system Endocarditis Other Source not identified Underlying disease Chronic obstructive pulmonary disease Arterial hypertension Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	83 (23.0) 45 (12.5) 30 (8.3)
Abdomen Urine Skin, bones, joints Catheter Central nervous system Endocarditis Other Source not identified Underlying disease Chronic obstructive pulmonary disease Arterial hypertension Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	83 (23.0) 45 (12.5) 30 (8.3)
Urine Skin, bones, joints Catheter Central nervous system Endocarditis Other Source not identified Underlying disease Chronic obstructive pulmonary disease Arterial hypertension Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	45 (12.5) 30 (8.3)
Skin, bones, joints Catheter Central nervous system Endocarditis Other Source not identified Underlying disease Chronic obstructive pulmonary disease Arterial hypertension Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	30 (8.3)
Catheter Central nervous system Endocarditis Other Source not identified Underlying disease Chronic obstructive pulmonary disease Arterial hypertension Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	
Central nervous system Endocarditis Other Source not identified Underlying disease Chronic obstructive pulmonary disease Arterial hypertension Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	
Endocarditis Other Source not identified Underlying disease Chronic obstructive pulmonary disease Arterial hypertension Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	7 (1.9)
Other Source not identified Underlying disease Chronic obstructive pulmonary disease Arterial hypertension Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	6 (1.7)
Source not identified Underlying disease Chronic obstructive pulmonary disease Arterial hypertension Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	6 (1.7)
Underlying disease Chronic obstructive pulmonary disease Arterial hypertension Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	8 (2.2)
Chronic obstructive pulmonary disease Arterial hypertension Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	11 (3.0)
Arterial hypertension Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	
Chronic heart failure Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	63 (17.4)
Liver cirrhosis Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	198 (54.5)
Chronic haemodialysis Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	36 (9.9)
Type 1 diabetes Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	27 (7.4)
Type 2 diabetes Immunocompromized state Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	8 (2.2)
Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	15 (4.1)
Active solid cancer Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	85 (23.4)
Active lymphoma or leukaemia Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	110 (<mark>30.3</mark>)
Myeloproliferative syndrome Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	45 (12.4)
Recent (<6 months) chemotherapy or radiotherapy Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	22 (6.1)
Neutropenia (absolute neutrophil count <1,000/mm³) HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	12 (3.3)
HIV seropositivity Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	42 (11.6)
Solid organ or bone marrow transplantation Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	27 (7.4)
Steroids therapy Other immunosuppressive therapy Criteria for circulatory failure at inclusion	4 (1.1)
Other immunosuppressive therapy Criteria for circulatory failure at inclusion	6 (1.7)
<mark>Criteria</mark> for <mark>circulatory</mark> <mark>failure</mark> at inclusion	41 (11.3)
	14 (3.9)
Tachycardia (heart rate >110 beats/minute)	
Urine output <0.5 mL/hour per Kg of body weight	195 (53.7)
Capillary refill time <mark>>2 seconds</mark>	195 (53.7) 147 (40.5)
Cyanosis in the absence of severe hypoxemia	
Skin <mark>mottling</mark>	147 (40.5)
Altered consciousness	147 (40.5) 48 (<mark>13.2</mark>)
Arterial <mark>lactate >2</mark> mmol/L on admission	147 (40.5) 48 (13.2) 56 (15.4)
Epinephrine or <mark>norepinephrine</mark> administration	147 (40.5) 48 (13.2) 56 (15.4) 167 (46.0)

Table 1 Demographics, clinical characteristics, treatment and outcome in 363 patients (Continued)

Therapy	
Invasive mechanical ventilation on admission	128 (35.2)
Invasive mechanical ventilation during ICU stay	305 (84.0)
Norepinephrine on admission	136 (37.5)
Epinephrine on admission	10 (2.8)
Norepinephrine or epinephrine during ICU stay	356 (<mark>98.1</mark>)
Dobutamine on admission	12 (3.3)
Transfusion of blood products between zero hours and 24 hours	58 (16.6)
Renal replacement therapy during ICU stay	84 (<mark>23.1</mark>)
Initial arterial blood lactate concentration,	3.2 ± 3.0
mmol/L ^a	median <mark>2.2</mark> (IQR 0.95 to 4.45)
McCabe classification [14]	
0	223 (61.4)
1	96 (26.4)
2	44 (12.1)
Simplified acute physiology score II [15]	56.8 ± 20.0
SOFA score [16] (highest value from H0 to H24)	10.3 ± 3.4
ICU death	102 (<mark>28.1</mark>)
Day- <mark>28 death</mark>	111 (<mark>30.6</mark>)

Categorical variables are expressed as absolute counts (%) and continuous variables as mean \pm SD unless otherwise specified. ^aInitial arterial blood lactate concentration was available in 358/363 patients (not measured in 5 patients because of technical problem). SOFA, Sequential organ failure assessment.

medians and IQR, as appropriate. The prevalence and 95% CI of $S_{\rm cv}O_2$ < 70% was estimated taking into account participating centres as a random effect [20]. The $S_{\rm cv}O_2$ < 70% and other thresholds of initial $S_{\rm cv}O_2$ values determined by locally weighted scatterplot smoothing (LOWESS) [21] were examined for their potential association with day-28 mortality.

Each given threshold of the initial $S_{\rm cv}O_2$ value was entered in a mixed-effect logistic regression model, with participating centres entered as a random effect, and adjusted for all covariables available at H0 and linked to day-28 mortality with a P-value <0.15, by univariate analysis. The covariables were eliminated using the backward method until the final logistic model with the best fit (as assessed by the Akaike information criterion [15]) was reached. Based on the results of a retrospective study performed in one participating ICU [22], we calculated that 1-year study duration would allow the inclusion of at least 350 patients with 100 fatalities, which would allow multivariate evaluation of ten covariables, including $S_{\rm cv}O_2$.

We re-ran the logistic analyses in predefined subgroups of patients (for example, mechanical ventilation or not at H0, patients below or above median values of continuous variables such as initial lactate level or amount of volume expansion before inclusion, et cetera).

Percentages were compared using the Fisher exact test, chi-square test, or chi-square test for trend (Cochran-Armitage test), and continuous variables were compared using the unpaired Student t-test or by analysis of variance when appropriate. Unadjusted comparisons of survival curves were performed using the log-rank test. Adjusted odds ratios (OR) are given with the 95% CI. A two-tailed P-value <0.05 was considered statistically significant. Mixed-effect logistic regression was performed using the lme4 package of R 2.15.2 [23].

Results

We screened 670 patients with severe sepsis or septic shock. Among them, 363 patients were enrolled (Figure 1). The Simplified acute physiology score (SAPSII) [24] and ICU death rates were similar in enrolled and non enrolled patients (see Additional file 2).

Demographic and clinical characteristics are shown in Table 1. The median time between ICU admission and inclusion (H0), and between the time at which criteria for inclusion were satisfied and inclusion, was 211 minutes (IQR 83 to 339) and 189 minutes (IQR 84 to 292), respectively. The median time between severe sepsis identification and inclusion (H0) was 7.6 hours (IQR 2 to 13.2). Details of resuscitation administered before inclusion and time of inclusion in patients classified according to their origin (transferred from another hospital, from the ward, or from the emergency department) are shown in Table 2.

The mean initial $S_{cv}O_2$ value was 74.1 \pm 11.0% and was not different between survivors and non survivors at day 28 (74.6 \pm 10.0% versus 73.0 \pm 12.9%, respectively; P = 0.21).

Prevalence of low initial ScvO2

Initial $S_{cv}O_2 < 70\%$ was present in 111 patients and the pooled estimate for its prevalence, taking into account participating centres as a random effect, was 27% (95% CI 18%, 37%). At H0, 136 patients (37%) had reached the classic clinical endpoints for mean arterial pressure (≥65 mmHg), central venous pressure (≥8 mmHg), and urine output (≥0.5 mL/Kg of body weight). Among them, 32% (43/136) had an initial $S_{cv}O_2 < 70\%$, with normal lactate concentration (≤2 mmol/L) in 21 (49%) patients. At H0, 166 patients (46%) had normal lactate concentration (≤2 mmol/L). Among them, 55 (33%) had an initial $S_{cv}O_2 < 70\%$. The delay between severe sepsis identification and inclusion and the amount of fluids administered for resuscitation before inclusion had no influence on the mean initial S_{cv}O₂ values or on the proportions of patients with initial $S_{cv}O_2 < 70\%$ (see Additional file 3).

Crude day-28 death rate and initial ScvO2 level

As determined by visual inspection of the LOWESS plot (see Additional file 4), we assessed the association between day-28 mortality and initial $S_{\rm cv}O_2 < 70\%$, <75%, and >85%. The day-28 death rate was significantly higher in patients with initial $S_{\rm cv}O_2 < 70\%$ than in patients with initial $S_{\rm cv}O_2 \ge 70\%$ (42/111 (37.8%) versus 69/252 (27.4%), respectively; P = 0.049), whereas it was similar in patients with initial $S_{\rm cv}O_2$ below or above the other thresholds examined (all P-values >0.35) (see Additional file 5: Table E8).

Association between $S_{cv}O_2$ and mortality when adjusted for potential confounders

The initial $S_{cv}O_2$ entered in the logistic model as a continuous variable was negatively linked to day-28 mortality: OR = 0.96 (95% CI 0.93, 0.99) for each 1% increase in initial $S_{cv}O_2$; P=0.004 (see Additional file 5: Table E9). An initial $S_{cv}O_2 < 70\%$ was significantly and independently associated with day-28 mortality (OR = 3.60, 95%CI 1.76, 7.36; P=0.0004) (Table 3), a trend consistently observed across the different subgroups examined (Figure 2).


An initial $S_{cv}O_2 < 75\%$ was also significantly associated with day-28 mortality (OR = 2.15, 95% CI 1.16 to 3.98; P = 0.015) (see Additional file 5: Table E10).

Evolution of $S_{cv}O_2$ and relationship to lactate concentration

The evolution of $S_{cv}O_2$ between H0 and H6 was similar between survivors and non survivors on day 28 (see Additional file 6: Figure E3). However, by logistic regression analysis, a $S_{cv}O_2 < 70\%$ at H6 still appeared as a risk factor for day-28 death (OR = 2.18, 95% CI 1.12, 4.26; P = 0.022) (see Additional file 5: Table E11).

The proportion of patients with initial $S_{cv}O_2 < 70\%$ was similar in the case of lactate above or below the median initial lactate value of 2.2 mmol/L (29% versus 33%; P = 0.3). Figure 3 shows the survival curves and the crude death rates at day 28 in four patients' subgroups according to their lactate concentration and $S_{cv}O_2$ at H0 (for subgroups according to lactate and $S_{cv}O_2$ at H6 see Additional file 6: Figure E4). In subgroup analysis, the logistic regression showed that $S_{cv}O_2 < 70\%$ was independently associated with day-28 death in patients with initial lactate level <2.2 mmol/L (OR = 3.31) (Figure 2).

Among the 335 patients with lactate and $S_{\rm cv}O_2$ measured at H0 and H6, 148 (44%) had a satisfactory lactate clearance (defined as at least a 10% decrease between H0 and H6 [25]) and 187 (56%) had not. The proportion of patients with $S_{\rm cv}O_2 < 70\%$ at H6 was similar in the case of satisfactory or not satisfactory lactate clearance (22% versus 23%, respectively). Additional file 6: Figure E5 shows the survival curves



and the crude death rates at day-28 in four patients' subgroups according to their lactate clearance and $S_{\rm cv}O_2$ at H0 and H6. On logistic regression, $S_{\rm cv}O_2$ < 70% at H6 was independently associated with day-28 mortality in the subgroup of patients with non satisfactory lactate clearance (OR = 2.32 (1.03, 5.23)) but

not in patients with satisfactory lactate clearance (OR = 0.98 (0.21, 4.54)). Additional results for the roles played by initial respiratory conditions, haemoglobin concentration and body temperature in the prevalence of low $S_{\rm cv}O_2$ and mortality are given in Additional file 7.

Table 2 Time of inclusion and resuscitation administered before inclusion

	Patients transferred from another hospital			Patients transferred from the emergency department	
	(n = 93)	(n = 95)	(n = 175)		
Patients intubated before inclusion	73 (78%)	72 (77%)	118 (67%)		
Amount of fluid administered before inclusion, mL/Kg					
of body weight	31	35	36		
	(12 to 50)	(19 to 51)	(20 to 52)		
Patients treated with vasopressors before inclusion					
(epinephrine or norepinephrine)	84 (<mark>88</mark> %)	82 (<mark>90</mark> %)	155 (<mark>89</mark> %)		
Dosage of vasopressors (epinephrine + norepinephrine),					
μg/Kg/min	0.3	0.26	0.40		
	(0.09 to 0.51)	(0.12 to 0.38)	(0.13 to 0.66)		
Patients treated with dobutamine before inclusion					
	3 (<mark>3%</mark>)	3 (<mark>3%</mark>)	10 (<mark>6%</mark>)		
Time between severe sepsis identification and					
inclusion, minutes	482	396	468		
	(220 to 510)	(40 to 847)	(188 to 696)		
Time between ICU admission and inclusion, minutes					
	185	246	206		
	(53 to 317)	(92 to 400)	(97 to 315)		
Time between satisfaction of inclusion criteria and					
inclusion, minutes	231	161	185		
	(110 to 352)	(60 to 262)	(93 to 277)		

Continuous variables are expressed as median and IQR, and categorical variables as number (%).

Discussion

The main finding of our study is that more than one quarter of septic patients had ScvO2 < 70% in the first hours after ICU admission. Furthermore, low ScvO2 in the first hours of ICU admission (and/or 6 hours later) was independently associated with 28-day mortality. These data suggest that one quarter of septic patients admitted to the ICU could be candidates for ICU protocol-based therapy targeting ScvO2.

Prevalence of low ScvO2

In the present multicentre study, using ScvO2 measurements planned as early as possible in routine care, we report a 27% prevalence of low ScvO2 (<70%). This value is below the 40% to 50% prevalence reported in the few, small sized, available prospective studies performed to date in the ICU [9,10]. These studies analysed selected patients: one study analysed only half of the patients with lactate above 3 mmol/L enrolled in a comparative therapeutic trial [9], and the other study excluded patients with malignancy [10]. However, the 27% prevalence of low ScvO2 we observed in our study with few exclusion criteria represents a non negligible proportion of septic patients and does not support the

view that low ScvO2 is uncommon after admission to the ICU [5-8].

Importantly, even when classic clinical endpoints of initial resuscitation were achieved (mean blood pressure (BP) >65 mmHg, central venous pressure (CVP) > 8 mmHg and urine output >0.5/ml/Kg) low ScvO2 could not be ruled out as it was observed in one third of our apparently resuscitated patients. Furthermore, arterial lactate also misclassified patients in their low/high contemporaneous ScvO2: the prevalence of ScvO2 < 70% was similar in the case of lactate above or below the median value of 2.2 mmol/L (29% versus 33%; P = 0.3). This underlines that ScvO2 measurement is not interchangeable with these routine clinical and biological data.

Association between low ScvO2 and outcome

As expected, the SAPSII score and the arterial lactate consistently appeared as powerful predictors of day-28 death. Independently of these two well-known predictors [24,26], low initial ScvO2 was also consistently linked to day-28 mortality. To the best of our knowledge, this has never been previously shown in either emergency department or ICU studies. Of note, our study was not designed to assess whether the link between low ScvO2 and mortality is a causal relationship.

Table 3 Logistic regression analysis of 28-day mortality in 363 septic patients, with initial S_{cv}O₂ value below 70% adjusted for the other confounders

Covariables ^a	Adjusted odds ratio ^b	95% CI	<i>P</i> -value
SAPSII (for each 1 point increase)	1.05	1.03, 1.07	<0.00001
Initial $S_{cv}O_2 < 70\%$	3. 60	1.76, 7.36	0.0004
Arterial lactate (for each 1 mmol/L increase)	1.18	1.06, 1.32	0.002
Initial arterial partial pressure in CO2 (for each 1 mmHg increase)	1.04	1.01, 1.06	0.003
McCabe class 1 (versus class 0)	2.58	1.31, 5.10	0.006
Abdominal sepsis	2.56	1.25, 5.23	0.010
McCabe class 2 (versus class 0)	3.09	1.24, 7.72	0.016
Male gender	2.14	1.11, 4.13	0.022
Initial body temperature (for each 1C° increase)	0.78	0.62, 0.98	0.031
Exposure to ACE inhibitors or ARB in the past 48 hours	0.50	0.26, 0.98	0.044

^aAll covariables entered in the model were variables linked to day-28 mortality with *P* <0.05 on univariate analysis, and selected using the backward method. ^bFor each continuous covariable odds ratios are given per each unit of the given covariable. ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blockers; SAPSII, Simplified acute physiology score; S_{cv}O₂, central venous oxygen saturation.


Clinical perspectives

One quarter of our septic patients had low ScvO2 in the first hours of ICU admission and this was associated with poor outcome. This was also the case for persisting low ScvO2 (at 6 hours after the first measurement). These patients could be candidates for ICU protocolbased therapy targeting the ScvO2 in addition to routine initial care. The choice between lactate-guided, ScvO2guided therapy, or between both, is still under debate [27]. In emergency department septic patients, there is no significant difference in patients' outcomes when managed either with lactate-guided or ScvO2-guided therapy [28]. Interestingly, our results suggest that, rather than choosing one of these measurements, ScvO2 should be tested in combination with lactate monitoring because low ScvO2 may be present or persist even in the case of low lactate, or in the case of satisfactory lactate clearance (see Figure 3 and Additional file 6). This later finding was also observed in studies performed in emergency department patients in the very early phase of resuscitation: Arnold et al. [29] have shown that 15% of patients with good lactate clearance and 21% of patients with poor lactate clearance had $S_{cv}O_2 < 70\%$; in the study by Jones et al. [28], an interventional, randomized trial comparing lactate clearance or $S_{cv}O_2 > 70\%$ as therapeutic targets, the proportion of patients who did not have normalized ScvO2 was 19% in both groups. This proportion is lower than the one we observed but may not reflect what happens in real conditions, as resuscitation was performed per protocol for the purpose of the randomized trial. For their part, Jansen et al. [9] compared usual care and protocol-based therapy with lactate clearance as a target in an ICU population of septic patients, and showed that at 6 hours, 33% of patients in the intervention group still had $S_{cv}O_2 < 70\%$ while more than 40% had lactate clearance >20%.

Although these findings are consistent with ours, once again they may not reflect the real-life conditions as the patients were treated according to a rigorous and complex protocol. Therefore, to our knowledge, our study is the first to show that $S_{cv}O_2$ and lactate may show non parallel evolutions in septic patients cared for in the ICU in real-life conditions.

The usefulness of protocol-based resuscitation including the normalization of ScvO2 has been recently challenged by the ProCESS trial [30], a randomized trial conducted in emergency departments in the very early phase of resuscitation of septic patients. This study showed no advantage in terms of survival with the protocol-based therapy including the normalization of S_{cv}O₂ as compared to usual care [30]. Of note, the ProCESS trial population was quite different from that we studied in our work, in which we estimated the prevalence of $S_{cv}O_2$ and of persisting $S_{cv}O_2$ in ICU patients, after the initial phase of resuscitation. On the other hand, in 1995 Gattinoni et al. [31] also showed that therapy aimed at normalizing the SvO2 value did not lead to better outcome than standard care in a general population of critically ill patients. Their results cannot be transposed to our study population as they included fewer than 25% of septic patients, and included them more than 48 hours after ICU admission [31], a time frame quite different from that used for inclusion in our work. For these reasons we believe it is premature to abandon the concept of normalization of S_{cv}O₂ in severely septic patients admitted to the ICU for whom low S_{cv}O₂ cannot be neglected, given its association with increased day-28 mortality. Further studies are required to precisely identify which ICU patients would benefit from therapeutic strategies aimed at S_{cv}O₂ normalization.

The LOWESS plot (see Additional file 4) used to identify cutoff values of initial $S_{cv}O_2$ illustrates that below ScvO2 of 75%, the lower the $S_{cv}O_2$ the lower was the



(See figure on previous page.)

Figure 2 Forest plot for subgroup analysis. ^aAll cutoff values provided in the figure for demographic, clinical or laboratory variables are median values calculated on the whole study population. ^bSequential organ failure assessment (SOFA) score is the highest value during the first 24 hours after enrollment. ^cWith the use of a cutoff of 2 mmol/L for lactate, the odds ratio for day-28 death (OR) was 1.29 (0.54, 3.05) in the case of lactate >2 mmol/L, and 4.59 (1.79, 11.84) in the case of lactate ≤2 mmol/L. ^dVasopressor dose = continuous intravenous (iv) norepinephrine dose plus continuous iv epinephrine dose. ^eLeft ventricular ejection fraction assessed by transthoracic echocardiography before 24 hours after enrollment. ^fHaemoglobin concentration was taken into account only if measured between 6 hours before and 6 hours after enrollment. SAPSII, Simplified acute physiology score; ScvO2, central venous oxygen saturation.

survival. Hence, S_{cv}O₂ < 75% was also associated with day-28 mortality in our multivariate analysis. This cutoff of 75% for worse outcome in our septic patients is higher than that found in cardiac failure patients [32,33]. This is consistent with the physiopathology of septic shock in which microcirculatory shunts lead to intraorgan oxygen extraction impairment that necessitates maintaining a high level of oxygen delivery to ensure adequate organ oxygen uptake [34]. Beyond the confirmation that S_{cv}O₂ of 70% is an important threshold for patient outcome, our study also suggests that, in septic patients, S_{cv}O₂ of 75% could be an even more relevant target that best ensures that overall tissue oxygenation is adequate in the context of septic oxygen extraction impairment. However, the thresholds of S_{cv}O₂ that could be proposed after the visual inspection of the LOWESS plot were statistically estimated cutoff values in the entire study population that may not apply at the individual level. Therefore, S_{cv}O₂ value of 67% for instance does not

necessarily place a given patient in a dangerous condition, and conversely an S_{cv}O₂ of 73% should not be seen as necessarily reassuring. In fact each individual patient probably has his/her own threshold from which it could be dangerous to deviate, depending on how his/her tissues are trained to extract oxygen in situations of high oxygen demand [35] or insufficient oxygen transport, and depending on the intensity of the microcirculatory shunts [36] linked to the severity of the sepsis process. In relation with this later issue, high values of ScvO2 may reflect the intensity of the microcirculatory derangements caused by sepsis. Some studies have suggested that either ScvO2 higher than 80% within the first 3 days in the ICU [37] or ScvO2 higher than 90% in the emergency department [38], were markers of poor prognosis. Indeed, although our study was underpowered to specifically examine the role of high values of S_{cv}O₂, we also observed that, beyond the threshold of 75%, the higher the S_{cv}O₂, the lower was the survival (see Additional file 4).




Figure 3 Survival curve and death rate (%) at day 28 according to initial lactate level and central venous oxygen saturation ($S_{cv}O_2$). The left part of the figure shows survival curves in four patients' subgroups according to their initial zero hours (H0) lactate concentration and $S_{cv}O_2$. The right part of the figure shows the day-28 death rate in each subgroup. Numbers inside the bars are number of non survivors/total number of patients in each subgroup. ^aUnadjusted pair comparison of survival curves between the different subgroups were not statistically significant on log-rank test. ^bThere was no significant difference in crude death rate at day-28 among the four groups (chi-squared test). However, there was a significant global trend towards higher death rate from the condition with normal lactate and $S_{cv}O_2$ to the condition with high lactate and low $S_{cv}O_2$ (P <0.001, Cochran-Armitage test).

Limitations of the study

First, this study was not designed to seek for the reasons of low S_{cv}O₂. Since we have not systematically measured cardiac output, we cannot distinguish between the roles played by too-low oxygen delivery on the one hand and too-high oxygen demand on the other hand. Second, our study was clearly underpowered to draw conclusions about the significance of high S_{cv}O₂ values. Third, in view of our inclusion rate, selection bias cannot be definitely ruled out. However, patients were not selected on the basis of the variable of interest (S_{cv}O₂), which was not known during the screening/enrolment process. Additionally, enrolled and non enrolled patients' characteristics were similar (see Additional file 2). Moreover, as shown in Additional file 2, the proportion of patients with low S_{cv}O₂ consistently ranged from around 24% to 36% in subgroups of patients classified according to their cardiac or respiratory status, or to the timing and intensity of therapeutic interventions performed before inclusion. Fourth, $S_{cv} O_2$ was not measured by the same method in all participating centres, as four used standard blood gas analysers and six used co-oximeters. This might have distorted the accurate determination of cutoff values of ScvO2, because the limits of agreement between both methods are wide [39]. However, this does not impair the general interpretation of our results as a majority (265/363) of the included patients had S_{cv}O₂ measured by co-oximetry and the link between low $S_{\rm cv} O_2$ and day-28 mortality remained statistically significant in this patient subgroup.

Conclusion

Our study demonstrated that, in septic patients, low levels of $S_{cv}O_2$ in the first hours of ICU admission were frequent (<70% for more than one quarter), even when clinical resuscitation endpoints are achieved and even when arterial lactate was normal. Importantly, $S_{cv}O_2$ in the first hours of ICU admission and/or six hours later was linked to day-28 mortality.

Key messages

- In septic shock patients, low $S_{\rm cv}O_2$ (<70%) is common in the first hours of admission to the ICU
- In septic shock patients, low S_{cv}O₂ (<70%) in the first hours of admission to the ICU is associated with increased day-28 mortality
- In addition to usual care, ICU protocol-based therapy targeting $S_{cv}O_2$ may be tested in controlled trials in septic patients with low or persisting low $S_{cv}O_2$ in the first hours of ICU admission

Additional files

Additional file 1: Clinical and laboratory data recorded.

Additional file 2: Comparison of enrolled and non enrolled patients and proportions of patients with low central venous oxygen saturation ($S_{cv}O_2$) in patients' subgroups.

Additional file 3: Inclusion delays and resuscitation before inclusion: influence on central venous oxygen saturation $(S_{cv}O_2)$.

Additional file 4: Association between central venous oxygen saturation ($S_{cv}O_2$) and day-28 survival as assessed by locally weighted scatterplot smoothing (LOWESS) plot.

Additional file 5: Thresholds of central venous oxygen saturation $(S_{CV}O_2)$ and mortality: bivariate and multivariate analyses.

Additional file 6: Evolution of central venous oxygen saturation from hour-zero (H0)n to H6.

Additional file 7: Roles of respiratory condition, haemoglobin, and body temperature.

Abbreviations

LOWESS: locally weighted scatterplot smoothing; OR: adjusted odds ratios; SAPSII: Simplified acute physiology score; $S_{cv}O_2$: central venous oxygen saturation; S_vO_2 : mixed venous oxygen saturation.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

TB conceived and coordinated the study, obtained funding, participated in the acquisition, analysis and interpretation of data, performed the statistical analysis and drafted the manuscript. DG participated to the study design, participated to the acquisition, analysis and interpretation of data, and helped to draft the manuscript. PV participated in the study design and acquisition, analysis and interpretation of data, and helped to draft the manuscript. AM, JBL, AD, VB, AF, JPF, FB and JPQ all participated in the study design and the acquisition, analysis and interpretation of data. PFD participated in the study design and the acquisition, analysis and interpretation of data, and helped to draft the manuscript. All authors read and approved the final manuscript.

Authors' information

Clinical Research in Intensive Care and Sepsis (CRICS) Group (http://www.crics.fr).

Acknowledgments

We are indebted to all participating investigators who collected data and cared for study patients: Olivier Baudin, Sylvie Calvat, Christophe Cracco, Arnaud Desachy, Charles Lafon (Angoulême, CRICS group); Emmanuelle Boitrou, Hervé Mentec, Olivier Pajot, Gaëtan Plantefève, Marina Thirion (Argenteuil, CRICS group); Rémi Bruyère, Jean-Pierre Quenot (Dijon, CRICS group); Konstantinos Bachoumas, Maud Fiancette, Jean Claude Lacherade, Jean Baptiste Lascarrou, Christine Lebert, Laurent Martin-Lefèvre, Jean Reignier, Isabelle Vinatier, Aihem Yehia (La Roche sur Yon, CRICS group); Emmanuelle Begot, Remy Bellier, Marc Clavel, Bruno François, Antoine Galy, Nicolas Pichon, Philippe Vignon (Limoges, CRICS group); Patrick Bardou, Michel Bonnivard, Anne Marco, Jérôme Roustan, Sylvie Vimeux (Montauban, CRICS group); Anne Bretagnol, Armelle Mathonnet, Dalila Benzekri, Nicolas Bercault, Thierry Boulain, Toufik Kamel, Grégoire Muller, François Réminiac, Isabelle Runge, Marie Skarzynski (Orléans, CRICS group); Delphine Chatellier, Rémi Coudroy, Jean-Pierre Frat, Véronique Goudet, René Robert, Anne Veinstein (Poitiers, CRICS group); Vlad Botoc, Stéphanie Chevalier, François Collet, Jean-Paul Gouello (Saint-Malo); Julie Badin, Pierre-François Deguin, Denis Garot, Antoine Guillon, Annick Legras, Elodie Masseret, Emmanuelle Mercier, Patrice Talec, (Tours, CRICS group).

Author details

¹Medical-Surgical Intensive Care Unit, Regional Hospital Center, Orléans, France. ²Medical Intensive Care Unit, University Hospital, Tours, France. ³Medical-Surgical Intensive Care Unit, University Hospital, Limoges, France. ⁴CIC-P 1435, Inserm U1092, Limoges, France. ⁵Medical-Surgical Intensive Care Unit, District Hospital Center, La Roche-sur-Yon, France. ⁶Medical-Surgical Intensive Care Unit, District Hospital Center, Angoulême, France. ⁷Medical-Surgical Intensive Care Unit, District Hospital Center, Saint-Malo, France. ⁸Medical-Surgical Intensive Care Unit, District Hospital Center,

Argenteuil, France. ⁹Medical Intensive Care Unit, University Hospital, Poitiers, France. ¹⁰Medical-Surgical Intensive Care Unit, District Hospital Center, Montauban, France. ¹¹Medical Intensive Care Unit, University Hospital, Dijon, France. ¹²INSERM, U866, Dijon, France. ¹³Clinical Research in Intensive Care and Sepsis (CRICS) Group, Tours, France.

Received: 31 May 2014 Accepted: 21 October 2014 Published online: 06 November 2014

References

- Rady MY, Rivers EP, Nowak RM: Resuscitation of the critically ill in the ED: responses of blood pressure, heart rate, shock index, central venous oxygen saturation, and lactate. Am J Emerg Med 1996, 14:218–225.
- Dueck MH, Klimek M, Appenrodt S, Weigand C, Boerner U: Trends but not individual values of central venous oxygen saturation agree with mixed venous oxygen saturation during varying hemodynamic conditions. Anesthesiology 2005. 103:249–257.
- Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative Group: Early Goal-Directed Therapy Collaborative Group: early goal directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368–1377
- 4. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580–637.
- Bellomo R, Reade MC, Warrillow SJ: The pursuit of a high central venous oxygen saturation in sepsis: growing concerns. Crit Care 2008, 12:130.
- Perel A: Bench-to-bedside review: the initial hemodynamic resuscitation of the septic patient according to Surviving Sepsis Campaign guidelines-does one size fit all? Crit Care 2008, 12:223.
- Peake S, Webb S, Delaney A: Early goal-directed therapy of septic shock: we honestly remain skeptical. Crit Care Med 2007, 35:994–995.
- van Beest PA, Hofstra JJ, Schultz MJ, Boerma EC, Spronk PE, Kuiper MA: The incidence of low venous oxygen saturation on admission to the intensive care unit: a multi-center observational study in The Netherlands. Crit Care 2008, 12:R33.
- Jansen TC, van Bommel J, Schoonderbeek FJ, Sleeswijk Visser SJ, van der Klooster JM, Lima AP, Willemsen SP, Bakker J, LACTATE study group: Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med 2010, 182:752–761
- Chung KP, Chang HT, Huang YT, Liao CH, Ho CC, Jerng JS, Yu CJ: Central venous oxygen saturation under non-protocolized resuscitation is not related to survival in severe sepsis or septic shock. Shock 2012, 38:584–591.
- Bracht H, Hänggi M, Jeker B, Wegmüller N, Porta F, Tüller D, Takala J, Jakob SM: Incidence of low central venous oxygen saturation during unplanned admissions in a multidisciplinary intensive care unit: an observational study. Crit Care 2007, 11:R2.
- Pope JV, Jones AE, Gaieski DF, Arnold RC, Trzeciak S, Shapiro NI, Emergency Medicine Shock Research Network (EMShockNet) Investigators: Multicenter study of central venous oxygen saturation (ScvO(2)) as a predictor of mortality in patients with sepsis. Ann Emerg Med 2010, 55:40–46.
- Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS: 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31:1250–1256.
- McCabe WR, Jackson GG: Gram-negative bacteremia I. Etiology and ecology. Arch Intern Med 1962, 110:847–891.
- Akaike H: A new look at statistical model identification. IEEE Trans Automat Contr 1974. 19:716–722.
- 16. Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related"

- problems" of the European Society of Intensive Care Med. *Crit Care Med* 1998. **26**:1793–1800.
- 17. French government: Loi 2004-806 (August 9, 2004) relative à la politique de santé publique. J French Repub 2004, 185:14277.
- Antonelli M, Levy M, Andrews PJ, Chastre J, Hudson LD, Manthous C, Meduri GU, Moreno RP, Putensen C, Stewart T, Torres A: Hemodynamic monitoring in shock and implications for management. International Consensus Conference, Paris, France, 27-28 April 2006. Intensive Care Med 2007, 33:575–590.
- Pottecher T, Calvat S, Dupont H, Durand-Gasselin J, Gerbeaux P, SFAR/ SRLF workgroup: Hemodynamic management of severe sepsis: recommendations of the French Intensive Care' Societies (SFAR/SRLF) Consensus Conference, 13 October 2005, Paris. France Crit Care 2006, 10:311.
- DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177–188.
- 21. Cleveland WS, Devlin SJ: Locally-weighted regression: an approach to regression analysis by local fitting. J Am Stat Assoc 1988, 83:596–610.
- Boulain T, Runge I, Benzekri-Lefèvre D, Mathonnet A, Bretagnol A, Fleury C: Saturation veineuse cave supérieure (ScvO2) à la prise en charge du sepsis sévère en réanimation : fréquence des valeurs basses [Abstract]. Reanimation 2011, 20:S226.
- R Core Team: R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. ISBN 3-900051-07-0 [http://www.R-project.org/]
- Le Gall JR, Lemeshow S, Saulnier F: A new simplified acute physiology score (SAPS II) based on a European/north American multicenter study. JAMA 1993, 270:2957–2963.
- Nguyen HB, Rivers EP, Knoblich BP, Jacobsen G, Muzzin A, Ressler JA, Tomlanovich MC: Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 2004, 32:1637–1642.
- Mikkelsen ME, Miltiades AN, Gaieski DF, Goyal M, Fuchs BD, Shah CV, Bellamy SL, Christie JD: Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med 2009, 37:1670–1677.
- Marik PE, Bellomo R: Lactate clearance as a target of therapy in sepsis: a flawed paradigm. OA Critical Care 2013, 1:3.
- Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA, Emergency Medicine Shock Research Network (EMShockNet) Investigators: Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA 2010, 303:739–746.
- Arnold RC, Shapiro NI, Jones AE, Schorr C, Pope J, Casner E, Parrillo JE, Dellinger RP, Trzeciak S, Emergency Medicine Shock Research Network (EMShockNet) Investigators: Multicenter study of early lactate clearance as a determinant of survival in patients with presumed sepsis. Shock 2009, 32:35–39.
- Investigators PCESS, Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, Pike F, Terndrup T, Wang HE, Hou PC, LoVecchio F, Filbin MR, Shapiro NI, Angus DC: A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014, 370:1683–1693.
- Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, Fumagalli R: A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med 1995, 333:1025–1032.
- 32. van Beest P, Wietasch G, Scheeren T, Spronk P, Kuiper M: Clinical review: use of venous oxygen saturations as a goal a yet unfinished puzzle. *Crit Care* 2011, **15**:232.
- Gallet R, Lellouche N, Mitchell-Heggs L, Bouhemad B, Bensaid A, Dubois-Randé
 JL, Gueret P, Lim P: Prognosis value of central venous oxygen saturation in
 acute decompensated heart failure. Arch Cardiovasc Dis 2012. 105:5–12.
- Astiz ME, Rackow EC, Falk JL, Kaufman BS, Weil MH: Oxygen delivery and consumption in patients with hyperdynamic septic shock. Crit Care Med 1987, 15:26–28.
- Kalliokoski KK, Oikonen V, Takala TO, Sipila H, Knuuti J, Nuutila P: Enhanced oxygen extraction and reduced flow heterogeneity in exercising muscle in endurance-trained men. Am J Physiol Endocrinol Metab 2001, 280:F1015–F1021
- Ellis CG, Bateman RM, Sharpe MD, Sibbald WJ, Gill R: Effect of a maldistribution of microvascular blood flow on capillary O(2) extraction in sepsis.
 Am J Physiol Heart Circ Physiol 2002, 282:H156–H164.
- 37. Textoris J, Fouché L, Wiramus S, Antonini F, Tho S, Martin C, Leone M: High central venous oxygen saturation in the latter stages of septic shock is associated with increased mortality. *Crit Care* 2011, 15:R176.

- 38. Ho BC, Bellomo R, McGain F, Ones D, Naka T, Wan L, Braitberg G: The incidence and outcome of septic shock patients in the absence of early-goal directed therapy. *Crit Care* 2006, 10:R80.
- Subramanian G, Anitha VP, Ranjit S: Comparison of central venous saturation by standard ABG machine versus co-oximeter: Is 18 carat as good as the 24 carat gold standard? *Indian J Crit Care Med* 2013, 17:82–86.

doi:10.1186/s13054-014-0609-7

Cite this article as: Boulain et al.: Prevalence of low central venous oxygen saturation in the first hours of intensive care unit admission and associated mortality in septic shock patients: a prospective multicentre study. Critical Care 2014 18:609.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

